^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YE-NEO 001

    i
    Other names: YE-NEO 001, neoepitope yeast vaccine
    Associations

    News

    Trials
    Company:
    ImmunityBio
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    11ms
    QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, NantBioScience, Inc. | Unknown status --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2025 | Trial primary completion date: Dec 2019 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HR positive + HER-2 positive
    |
    YE-NEO 001